Second Bisantrene Patent Allowed in US
Released
Released
Announcement PDF
21 February 2018
ASX Announcement / Media Release
Second Bisantrene Patent Allowed in US
HIGHLIGHTS
● US Patent Office grants Notice of Allowance on second key Bisantrene patent
● Extends value of Bisantrene to new formulations
21 February 2018: Race Oncology Limited (“RAC”) is pleased to announce that the second
Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a
jurisdiction, a patent can proceed to a ‘granted’ patent.
The patent titled, “Compositions to Improve the Therapeutic Benefit of Bisantrene and
Analogs and Derivatives Thereof,” is the second of two Bisantrene patents filed in the US,
Europe and five other key countries.
“After announcing our first patent allowance last month, we are very pleased to see our
second patent also allowed in the world’s most important pharmaceutical market,” said Race
CEO, Peter Molloy.
This patent provides commercial protection for new formulations of Bisantrene.
“We have been developing second-generation Bisantrene formulations with potentially
improved characteristics over the current Bisantrene product,” noted Mr Molloy. “This patent
provides commercial protection for these potential new products.”
About Bisantrene
Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most
frequently prescribed cancer drugs and first line of treatment for many cancers. It has been
shown to have greatly reduced cardiac toxicity and significantly diminished potential for
resistance. Bisantrene was tested in more than 40 clinical studies before it was lost in a series
of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for
relapsed/refractory AML patients. The FDA has acknowledged that Race’s Bisantrene
program meets the criteria as a 505(b)(2) program. Race has filed two patents on the drug
Race Oncology Ltd ABN 61 149 318 749
Registered office: L2, 710 Collins St, Docklands VIC Australia 3008
www.raceoncology.com
and has been granted an Orphan Drug Designation in the USA for AML, which confers seven
years of market exclusivity in the US from the date of FDA approval.
About Bisantrene Patents
Race Oncology owns two patents on Bisantrene: (1) “Combinatorial Methods to Improve the
Therapeutic Benefit of Bisantrene and Analogs and Derivatives Thereof,” and (2)
“Compositions to Improve the Therapeutic Benefit of Bisantrene and Analogs and Derivatives
Thereof.” The two patents filed between 2014 and 2016 in United States (US), Europe,
Canada, China, South Korea, Australia and New Zealand. If granted, both patents will last 20
years from filing, expiring in 2034. Both patents are wholly-owned by Race Oncology with no
royalty obligations to any third party.
About Race Oncology (RAC.ASX)
Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities
Exchange (ASX) in July 2016. Race’s business model is to pursue later-stage drug assets in the
cancer field that have been overlooked by big pharma. The company’s first asset is Bisantrene,
a chemotherapy drug, that was the subject of more than 40 phase II clinical studies during the
1980s and 1990s, then lost in a series of pharmaceutical mergers.
Media contact:
Heidi Cuthbert
+61 411 272 366
E: heidi.cuthbert@multiplier.com.au
Race Oncology Ltd ABN 61 149 318 749
Registered office: L2, 710 Collins St, Docklands VIC Australia 3008
www.raceoncology.com
Share your feedback
Discover